NEW YORK, NY / ACCESSWIRE / June 13, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
XRAY Shareholders Click Here: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-submission-form?prid=28511&wire=1
FHS Shareholders Click Here: https://www.zlk.com/pslra-1/first-high-school-education-group-co-ltd-loss-submission-form?prid=28511&wire=1
AXSM Shareholders Click Here: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=28511&wire=1
* ADDITIONAL INFORMATION BELOW *
Dentsply Sirona Inc. (NASDAQ:XRAY)
This lawsuit is on behalf of all persons or entities that purchased Dentsply’s common stock between June 9, 2021, and May 9, 2022.
Lead Plaintiff Deadline: August 1, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/dentsply-sirona-inc-loss-submission-form?prid=28511&wire=1
According to the filed complaint, defendants orchestrated a scheme to inflate Dentsply’s revenue and earnings by manipulating the Company’s accounting for a distributor rebate program so that senior executives would be eligible for significant cash and stock-based incentive compensation. In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the class period. As a result of defendants’ misrepresentations, Dentsply’s common stock traded at artificially inflated prices during the class period.
First High-School Education Group Co., Ltd. (NYSE:FHS)
This lawsuit is on behalf of all persons or entities who purchased FHS American Depositary Shares in or traceable to the Company’s March 2021 initial public offering.
Lead Plaintiff Deadline: July 11, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/first-high-school-education-group-co-ltd-loss-submission-form?prid=28511&wire=1
According to the filed complaint, (a) the new rules, regulations and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the Company and its business; (b) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on FHS’s enrollment and growth; and (c) as a result, representations made in connection with the Company’s initial public offering regarding FHS’s historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company at the time of the initial public offering, and were materially false and misleading and lacked a factual basis.
Axsome Therapeutics, Inc. (NASDAQ:AXSM)
AXSM Lawsuit on behalf of: investors who purchased December 30, 2019 – April 22, 2022
Lead Plaintiff Deadline: July 12, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/axsome-therapeutics-inc-information-request-form?prid=28511&wire=1
According to the filed complaint, during the class period, Axsome Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome’s chemistry, manufacturing, and control (“CMC”) practices were deficient with respect to AXS-07, the Company’s medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application (“NDA”) on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration (“FDA”) reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07’s regulatory and commercial prospects; and (vi) as a result, the Company’s public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP
View source version on accesswire.com:
https://www.accesswire.com/704990/CLASS-ACTION-UPDATE-for-XRAY-FHS-and-AXSM-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders
